Sign In
Buy SNDX
$18.34
-0.0500 (-0.272%)
At Close: Jun 03, 2026
Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth
10:08pm, Saturday, 29'th Nov 2025
Syndax Pharmaceuticals (SNDX) posted strong Q3 results, driven by robust Revuforj and Niktimvo sales, despite a slight revenue miss. SNDX's commercial ramp is accelerating, with Revuforj prescriptions
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 10.9% After Analyst Upgrade
01:21am, Tuesday, 25'th Nov 2025
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report)'s stock price was up 10.9% during mid-day trading on Monday after Barclays raised their price target on the stock from $22.00 to $35.00. B
Campbell & CO Investment Adviser LLC Invests $439,000 in Syndax Pharmaceuticals, Inc. $SNDX
04:37am, Monday, 17'th Nov 2025
Campbell and CO Investment Adviser LLC purchased a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) in the undefined quarter, according to its most recent 13F filing with the Securit
Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript
02:01pm, Monday, 10'th Nov 2025
Syndax Pharmaceuticals, Inc. ( SNDX ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Michael Metzger - CEO & Director Nicholas Botwood - Head of Research & D
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 05'th Nov 2025
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November
Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026
11:57am, Wednesday, 05'th Nov 2025
Syndax Pharmaceuticals, Inc. remains a Buy, with Revuforj and Niktimvo launches accelerating and a strong clinical and commercial trajectory into 2026. Revuforj's recent NPM1 AML approval expands its
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates
11:58pm, Monday, 03'rd Nov 2025
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.7 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to a loss of $0.98 per share a year ago.
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call Transcript
09:06pm, Monday, 03'rd Nov 2025
Syndax Pharmaceuticals, Inc. ( SNDX ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Sharon Klahre - Vice President of Investor Relations & Communications Michael Metzger - CE
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
04:01pm, Monday, 03'rd Nov 2025
– $45.9 million in total revenue, representing 21% growth over 2Q25 – – $32.0 million Revuforj ® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25, highlig
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
09:08am, Monday, 03'rd Nov 2025
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax's leadership in menin inhibition and CSF-1R inhibition –
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
09:08am, Monday, 03'rd Nov 2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company
AlphaQuest LLC Sells 18,370 Shares of Syndax Pharmaceuticals, Inc. $SNDX
04:04am, Monday, 03'rd Nov 2025
AlphaQuest LLC trimmed its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) by 46.7% in the second quarter, according to the company in its most recent filing with the SEC. The firm owne
Syndax Announces Participation in November Investor Conferences
07:00am, Thursday, 30'th Oct 2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
07:00am, Monday, 27'th Oct 2025
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will repo
Syndax Expands Revuforj Approval, Buy
11:44pm, Sunday, 26'th Oct 2025
Syndax Pharmaceuticals received expanded FDA approval for Revuforj, tripling its addressable AML patient population despite a boxed safety warning. Revumenib remains the only FDA-approved menin inhibi
